CN1655827B - 腺病毒和编码其的核酸的新应用 - Google Patents

腺病毒和编码其的核酸的新应用 Download PDF

Info

Publication number
CN1655827B
CN1655827B CN03812310XA CN03812310A CN1655827B CN 1655827 B CN1655827 B CN 1655827B CN 03812310X A CN03812310X A CN 03812310XA CN 03812310 A CN03812310 A CN 03812310A CN 1655827 B CN1655827 B CN 1655827B
Authority
CN
China
Prior art keywords
cell
adenovirus
use according
tumor
nuclear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN03812310XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1655827A (zh
Inventor
佩尔·松内·霍尔姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2002123534 external-priority patent/DE10223534A1/de
Application filed by Individual filed Critical Individual
Publication of CN1655827A publication Critical patent/CN1655827A/zh
Application granted granted Critical
Publication of CN1655827B publication Critical patent/CN1655827B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN03812310XA 2002-05-27 2003-05-27 腺病毒和编码其的核酸的新应用 Expired - Fee Related CN1655827B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DE10223534.1 2002-05-27
DE2002123534 DE10223534A1 (de) 2002-05-27 2002-05-27 Verwendung von Adenoviren und dafür codierenden Nukleinsäuren
DE10225400.1 2002-06-07
DE10225400 2002-06-07
DE10248039 2002-10-15
DE10248039.7 2002-10-15
DE10322530.7 2003-05-19
DE10322530 2003-05-19
PCT/EP2003/005583 WO2003099859A2 (de) 2002-05-27 2003-05-27 Neue verwendung von adenoviren und dafür codierenden nukleinsäuren

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201010161559.4A Division CN101843641B (zh) 2002-05-27 2003-05-27 腺病毒和编码其的核酸的新应用

Publications (2)

Publication Number Publication Date
CN1655827A CN1655827A (zh) 2005-08-17
CN1655827B true CN1655827B (zh) 2010-06-23

Family

ID=29587746

Family Applications (2)

Application Number Title Priority Date Filing Date
CN03812310XA Expired - Fee Related CN1655827B (zh) 2002-05-27 2003-05-27 腺病毒和编码其的核酸的新应用
CN201010161559.4A Expired - Fee Related CN101843641B (zh) 2002-05-27 2003-05-27 腺病毒和编码其的核酸的新应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201010161559.4A Expired - Fee Related CN101843641B (zh) 2002-05-27 2003-05-27 腺病毒和编码其的核酸的新应用

Country Status (9)

Country Link
US (5) US20060099178A1 (enExample)
EP (1) EP1506021B1 (enExample)
JP (3) JP5213298B2 (enExample)
KR (1) KR101083450B1 (enExample)
CN (2) CN1655827B (enExample)
AU (2) AU2003242585A1 (enExample)
CA (1) CA2487811A1 (enExample)
WO (1) WO2003099859A2 (enExample)
ZA (1) ZA200409361B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003242585A1 (en) 2002-05-27 2003-12-12 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
EP1689445B1 (de) * 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
WO2005052143A2 (de) * 2003-11-14 2005-06-09 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
US8361976B2 (en) 2004-07-09 2013-01-29 University Of Massachusetts Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules
EP1831382B1 (en) 2004-12-31 2023-01-18 Per Sonne Holm Method for reversing multiple resistance in animal cells
US20090232800A1 (en) * 2004-12-31 2009-09-17 Per Sonne Holm E1-minus adenoviruses and use thereof
WO2012022496A2 (en) 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
SG11201507393TA (en) * 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
SG11202007873VA (en) * 2018-03-05 2020-09-29 Klinikum Rechts Der Isar Der Technischen Univ Muenchen Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
SG11202012978VA (en) 2018-06-25 2021-01-28 Ospedale San Raffaele Srl Gene therapy
WO2021044061A1 (en) 2019-09-05 2021-03-11 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
EP4123021A4 (en) * 2020-03-23 2024-05-15 Curigin Co.,Ltd. STRUCTURE OF AN ONCOLYTIC VIRUS WITH BISPECIFIC NUCLEIC ACID MOLECULE
CN114540349B (zh) * 2020-11-27 2024-11-22 中国科学院分子细胞科学卓越创新中心 结合yb-1蛋白的核酸分子
CA3233100A1 (en) 2021-09-23 2023-03-30 Sagittarius Bio, Inc. Adenoviruses and methods for using adenoviruses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241632A (zh) * 1998-07-15 2000-01-19 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US931830A (en) * 1907-09-17 1909-08-24 Harry Zimmerman Material-cutter.
US4947842A (en) 1988-09-22 1990-08-14 Medical Engineering And Development Institute, Inc. Method and apparatus for treating tissue with first and second modalities
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
DK0689447T3 (da) * 1993-02-16 1999-10-18 Onyx Pharma Inc Cytopatiske vira til behandling af og profylakse for neoplasia
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
EP0784690B1 (en) 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
ATE386130T1 (de) 1995-03-24 2008-03-15 Genzyme Corp Adenovirale vektoren für die gentherapie
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
AU7674896A (en) 1995-10-31 1997-05-22 Board Of Regents, The University Of Texas System Adenovirus-antisense k-ras expression vectors and their application in cancer therapy
US6022863A (en) 1996-05-21 2000-02-08 Yale University Regulation of gene expression
US6730662B1 (en) * 1996-07-05 2004-05-04 Mcgill University Adenovirus E4 proteins for inducing cell death
DE69725882T2 (de) 1996-07-05 2004-07-29 Branton, Philip E., St. Lambert Adenovirus e4 proteine für induktion von zelltod
ES2188985T3 (es) 1996-08-30 2003-07-01 Jens Peter Furste Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
WO1998021350A1 (en) 1996-11-13 1998-05-22 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US6080578A (en) 1996-12-31 2000-06-27 Onyx Pharmaceuticals, Inc. Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia
US6100086A (en) 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
DE69838584T2 (de) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1905304A3 (en) 1997-10-09 2008-08-13 Wellstat Biologics Corporation Treatment of neoplasms with viruses
EP1121442A2 (en) 1998-10-15 2001-08-08 CANJI, Inc. Recombinant e1a deleted adenoviral vectors
US6649158B1 (en) 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
DE19860602A1 (de) 1998-12-29 2000-07-06 Max Delbrueck Centrum Gentransfervektor für die Diagnostik und die Therapie von malignen Tumoren
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
GB9906815D0 (en) 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
DE19929569A1 (de) 1999-06-21 2000-12-28 Holm Per Sonne Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1
WO2001002556A2 (de) 1999-06-30 2001-01-11 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur diagnose, prognose und therapie maligner erkrankungen
US6955808B2 (en) 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
EP1223947A4 (en) * 1999-10-15 2004-12-08 Canji Inc TARGETED VECTORS
US6140126A (en) 1999-10-26 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of Y-box binding protein 1 expression
WO2001036650A2 (en) * 1999-11-15 2001-05-25 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
DE10015413A1 (de) 2000-03-23 2001-09-27 Max Delbrueck Centrum Mittel zur Diagnose und Therapie viraler Erkrankungen
EP1301612A2 (en) 2000-05-31 2003-04-16 Genvec, Inc. Method and composition for targeting an adenoviral vector
AU784975B2 (en) 2000-10-11 2006-08-10 Sumitomo Chemical Company, Limited DNA-binding protein YB-1-containing collagen accumulation inhibitors
WO2002042468A2 (en) 2000-11-27 2002-05-30 Geron Corporation Glycosyltransferase vectors for treating cancer
US20030095989A1 (en) 2000-12-18 2003-05-22 Irving John M. Chimeric cytolytic viruses for cancer treatment
DE50112463D1 (de) 2000-12-28 2007-06-14 Per Sonne Holm Adenovirale systeme und deren anwendungen
DE10150945A1 (de) 2001-10-16 2003-04-17 Holm Per Sonne Adenovirale Systeme und deren Anwendungen
US20030138405A1 (en) 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
JP3974894B2 (ja) 2001-09-14 2007-09-12 財団法人新産業創造研究機構 腫瘍特異的プロモーターおよびその用途
DE10150984A1 (de) 2001-10-16 2003-04-17 Holm Per Sonne Verwendung des adenoviralen E2-late-Promotors
CA2478508C (en) 2002-04-25 2013-07-02 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
AU2003242585A1 (en) 2002-05-27 2003-12-12 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
PL219321B1 (pl) 2002-10-15 2015-04-30 Per Sonne Holm Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny
EP1616016B1 (en) 2003-03-19 2012-11-14 Isogenis, Inc. Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain
EP1689445B1 (de) 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
WO2005052143A2 (de) 2003-11-14 2005-06-09 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
WO2006065827A2 (en) 2004-12-13 2006-06-22 Canji, Inc. Cell lines for production of replication-defective adenovirus
EP1831382B1 (en) 2004-12-31 2023-01-18 Per Sonne Holm Method for reversing multiple resistance in animal cells
US20090232800A1 (en) 2004-12-31 2009-09-17 Per Sonne Holm E1-minus adenoviruses and use thereof
WO2007103825A2 (en) 2006-03-02 2007-09-13 The Board Of Regents Of The University Of Texas System Combination therapy with oncolytic adenovirus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241632A (zh) * 1998-07-15 2000-01-19 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Per S. Holm et al.YB-1 relocates to the nucleus in adenovirus-infected cells andfacilitates viral replication by inducing E2 gene expressionthrough the E2 late promoter.The Journal of Biological Chemistry277 12.2002,277(12),10427-10434页. *
刘然义;罗慧玲;彭吉林;蔡体育;张昌卿;潘伟光;吴沛宏;黄文林;曾益新.E1B缺陷腺病毒对鼻咽癌CNE-2细胞杀伤作用及其机理研究.中国肿瘤生物治疗杂志9 1.2002,9(1),6-9. *

Also Published As

Publication number Publication date
US20060099178A1 (en) 2006-05-11
AU2003242585A2 (en) 2003-12-12
CA2487811A1 (en) 2003-12-04
US10155930B2 (en) 2018-12-18
JP2014224141A (ja) 2014-12-04
ZA200409361B (en) 2005-08-31
US20190055522A1 (en) 2019-02-21
KR101083450B1 (ko) 2011-11-16
EP1506021A2 (de) 2005-02-16
AU2010219364A1 (en) 2010-09-30
CN101843641B (zh) 2014-09-17
EP1506021B1 (de) 2019-05-01
CN1655827A (zh) 2005-08-17
US10731136B2 (en) 2020-08-04
KR20050008744A (ko) 2005-01-21
US11268073B2 (en) 2022-03-08
US20200095560A1 (en) 2020-03-26
WO2003099859A2 (de) 2003-12-04
AU2003242585A1 (en) 2003-12-12
AU2010219364B2 (en) 2011-06-09
CN101843641A (zh) 2010-09-29
US10538744B2 (en) 2020-01-21
JP5213298B2 (ja) 2013-06-19
JP2006512284A (ja) 2006-04-13
US20110033424A1 (en) 2011-02-10
JP5719800B2 (ja) 2015-05-20
US20180002674A1 (en) 2018-01-04
WO2003099859A3 (de) 2004-04-15
JP2012179058A (ja) 2012-09-20

Similar Documents

Publication Publication Date Title
US11268073B2 (en) Use of adenovirus and nucleic acids coding therefor
JP5873893B2 (ja) アデノウイルスおよびそれをコードしている核酸の新たな使用
AU2010257327C1 (en) Adenovirus expressing genes in reverse order and use thereof
RU2393221C2 (ru) Аденовирус с обращенной генной экспрессией и его применение
CN1705740B (zh) 具有反向基因表达的腺病毒及其应用
AU2015201828B2 (en) Novel use of adenoviruses and nucleic acids coding therefor
CN101538556B (zh) 腺病毒选择性互补复制的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100623

Termination date: 20210527